Literature DB >> 2943759

Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients.

G B Pier, D Desjardins, T Aguilar, M Barnard, D P Speert.   

Abstract

We tested nonmucoid Pseudomonas aeruginosa isolates obtained from cystic fibrosis (CF) patients for the expression of lipopolysaccharide (LPS) serotype antigens, serum sensitivity, and production of mucoid exopolysaccharide (MEP). When all nonmucoid isolates were compared with a set of random mucoid isolates, 20 of 52 (38%) nonmucoid isolates were typable and serum resistant, compared with 13 of 51 (24%) mucoid isolates (P = 0.16 by chi-square analysis). However, nonmucoid strains from CF patients colonized only with nonmucoid strains were more frequently typable and serum resistant (67%) than were nonmucoid isolates from patients cocolonized with mucoid strains (31%) (P = 0.012, Fisher exact test). An inhibition enzyme-linked immunosorbent assay done with bacterial extracts, a direct-whole-cell enzyme-linked immunosorbent assay done with affinity-purified antibody to MEP, and immune electron microscopy all demonstrated production of MEP by all nonmucoid P. aeruginosa isolates tested, including nonmucoid revertants of mucoid strains. No other bacterial species tested positive in these assays. These findings suggest that MEP is produced by all P. aeruginosa isolates obtained from CF patients, that the initial colonizing nonmucoid strains produce a smooth LPS, and that once LPS-rough, mucoid strains appear in the sputum, the predominant LPS phenotype is rough regardless of colony morphology.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943759      PMCID: PMC268873          DOI: 10.1128/jcm.24.2.189-196.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; T McVeigh; P Owen
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

2.  A new modification of the carbazole analysis: application to heteropolysaccharides.

Authors:  C A Knutson; A Jeanes
Journal:  Anal Biochem       Date:  1968-09       Impact factor: 3.365

3.  Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature.

Authors:  P A di Sant'agnese; P B Davis
Journal:  Am J Med       Date:  1979-01       Impact factor: 4.965

4.  Serotypes and antibiotic susceptibilities of Pseudomonas aeruginosa isolates from single sputa of cystic fibrosis patients.

Authors:  T W Seale; H Thirkill; M Tarpay; M Flux; O M Rennert
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

5.  Outer membrane of Pseudomonas aeruginosa: heat- 2-mercaptoethanol-modifiable proteins.

Authors:  R E Hancock; A M Carey
Journal:  J Bacteriol       Date:  1979-12       Impact factor: 3.490

6.  Epidemiological markers for Pseudomonas aeruginosa. 6. Relationship between concomitant non-mucoid and mucoid strains from the respiratory tract in cystic fibrosis.

Authors:  T Bergan; N Hoiby
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1975-12

7.  Epidemiology of Pseudomonas aeruginosa infection in patients treated at a cystic fibrosis centre.

Authors:  N Høiby; K Rosendal
Journal:  Acta Pathol Microbiol Scand B       Date:  1980-06

8.  Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs.

Authors:  J E Pennington; W F Hickey; L L Blackwood; M A Arnaut
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

9.  Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa.

Authors:  G B Pier; D M Thomas
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

10.  Flagellar preparations from Pseudomonas aeruginosa: animal protection studies.

Authors:  I A Holder; R Wheeler; T C Montie
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

View more
  31 in total

1.  Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung.

Authors:  G B Pier; M Grout; T S Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis.

Authors:  D P Speert; S W Farmer; M E Campbell; J M Musser; R K Selander; S Kuo
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

3.  Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model.

Authors:  Alessandra Bragonzi; Dieter Worlitzsch; Gerald B Pier; Petra Timpert; Martina Ulrich; Morten Hentzer; Jens Bo Andersen; Michael Givskov; Massimo Conese; Gerd Doring
Journal:  J Infect Dis       Date:  2005-06-24       Impact factor: 5.226

4.  The algT gene of Pseudomonas syringae pv. glycinea and new insights into the transcriptional organization of the algT-muc gene cluster.

Authors:  Alexander Schenk; Michael Berger; Lisa M Keith; Carol L Bender; Georgi Muskhelishvili; Matthias S Ullrich
Journal:  J Bacteriol       Date:  2006-09-29       Impact factor: 3.490

5.  Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M Fegan; P Francis; A C Hayward; G H Davis; J A Fuerst
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

6.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

7.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

8.  Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection.

Authors:  Fadie T Coleman; Simone Mueschenborn; Gloria Meluleni; Christopher Ray; Vincent J Carey; Sara O Vargas; Carolyn L Cannon; Frederick M Ausubel; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

Review 9.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 10.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.